Medify Health Expands Subscription Platform with Remote Diagnostics and AI-Driven Medication Management
Cincinnati – November 25, 2025 Medify Health today announced the nationwide rollout of two new features inside its subscription-based primary-care platform: real-time remote diagnostics and AI-supported medication management. The tools, embedded in the company’s existing mobile app and Bluetooth-enabled devices, allow clinicians to detect deteriorating chronic conditions up to 10 days earlier than standard office-based follow-ups and to adjust prescriptions without requiring an in-person visit.
Remote patient monitoring has moved from pilot programs to “a mainstream component of U.S. healthcare delivery” in 2025, with more than 53 million Americans now enrolled in some form of digitally enabled care.
Medify’s upgrade arrives as CMS projects a 15 % year-over-year increase in reimbursement codes for remote physiologic monitoring, signaling sustained payer support. A June 2025 study in PLOS One found that personalized telehealth interventions reduced emergency-department use 22 % among diabetic patients—the exact population that comprises 38 % of Medify’s subscriber base.
“We are witnessing a fundamental shift from episodic, fee-for-service care to continuous, data-driven relationships,” said Brent Wise, President and CEO of Medify Health. “By bundling diagnostics and pharmacy oversight into one flat monthly fee, we have effectively eliminated the two biggest gaps in chronic-disease management: late clinical signals and medication errors.”
The diagnostics layer captures daily vitals—blood pressure, weight, glucose, pulse oximetry and spirometry—via FDA-cleared cellular devices shipped to the member’s home. Abnormal trends trigger an alert inside Medify’s EMR-integrated clinician dashboard within 60 seconds, prompting a telehealth consult that same day. The medication module cross-reals the patient’s current prescription list against the latest vital data and evidence-based protocols; machine-learning models, trained on 4.2 million de-identified encounters, flag duplications, contraindications or untreated indications and auto-generate a pharmacist-approved titration plan. Early adopters in a 500-member beta conducted between March and September 2025 saw hospital readmissions fall from 14.2 % to 6.9 %—a 51 % relative reduction—while Medicare’s Care Quality measure for medication adherence rose 27 %.
Market analysts expect the broader remote-monitoring sector to reach $175 billion globally by 2027, but adoption has been uneven among smaller primary-care practices that lack capital expenditure budgets. Medify’s subscription model—priced at $89 per month for individuals and $149 for families—removes upfront device costs and includes unlimited clinician consults, positioning the company to capture an estimated 4 % of the 38 million Americans with multiple chronic conditions within the next 24 months.
The new features are live in 38 states, with full national coverage scheduled by Q1 2026. Existing members received an over-the-air app update last night; new enrollees will be shipped diagnostic kits within 48 hours of sign-up.
About Medify Health
Launched in 2021, Medify Health operates a turnkey subscription platform that combines remote patient monitoring, chronic-care management and tele-pharmacy services. The Cincinnati-based company is recognized by Medical Care Review as the 2025 Top Remote Patient Monitoring Service and serves more than 220,000 members through partnerships with 1,700 independent practices and health systems nationwide.
Media Contact
Sarha Al-Mansoori
Director of Corporate Communications
G42
Email: media@g42.a
Phone: +971 2555 0100
Website: www.g42.ai
